Domestic pharmaceutical companies have reached a number of license-out transactions, further expanding overseas markets

Although the number of cross-border M&A transactions has decreased this year, the license-in, license-out transactions of pharmaceuticals still maintain a sustained high growth
.
According to statistics, domestic multi-pharmaceutical companies achieved license-out transactions in March, and through license-out transactions, domestic pharmaceutical companies will also further promote product development in the international market and accelerate the commercialization process
.
For example, on March 31, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) has entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis), granting the latter a transdermal transdermal drug of Lesotho Exclusive commercialization rights for the patch in Mexico and Poland
.
The data show that the Ristigmine Multi-Day Transdermal Patch is an innovative twice-weekly patch formulation of Ristigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease
.
The product was developed by Luye Pharma's proprietary transdermal drug delivery technology platform and has obtained marketing approvals in several European countries
.
It is reported that Luye Pharma is accelerating the development and commercialization of the Ristigmine transdermal patch in the global market
.
On March 30, Boaoxin Bio announced that it signed a licensing agreement with Pyxis oncology (NASDAQ: PYXS)
.
Under the agreement, Pyxis Oncology will receive an exclusive license for the global development and commercialization of Boaoxin BSI-060T, excluding Greater China
.
Under the terms of the agreement, Boosin will receive a $10 million down payment from Pyxis Oncology
.
In addition to the down payment, Boosin will be eligible to receive milestone payments totaling up to $222.
5 million and royalties up to a double-digit percentage of sales
.
Pyxis Oncology plans to file an IND filing with the FDA for PYX-106 in the second half of 2022 and start a Phase 1 clinical trial as soon as possible
.
Under this agreement, Pyxis Oncology will have the opportunity to introduce next-generation product rights around the Siglec-15 target from Boosin
.
Boaoxin said that the authorization of the global development rights of the anti-Siglec-15 antibody to Pyxis Oncology this time further demonstrates the advantages of the company's drug discovery engine in the development of antibody drug therapies
.
On March 17, Shenzhen Kangtai Biological Products Co.
, Ltd.
signed a framework agreement with Phil.
Pharmawealth Inc.
, an importer of injectable drugs in the Philippines, to jointly promote the registration of the 23-valent pneumococcal polysaccharide conjugate vaccine in the Philippines Agree on matters such as application and commercial sales
.
According to the data, the 23-valent pneumococcal polysaccharide vaccine of "Weimin Feile" was independently developed by Beijing Minhai Biological, a wholly-owned subsidiary of Kangtai Bio, and is a double-dose (prefilled syringe and vial) 23-valent pneumococcal polysaccharide vaccine for Prevention of pneumonia, meningitis, otitis media and bacteremia caused by 23 pneumococcal serotypes
.
The signing of a cooperation agreement with a Philippine pharmaceutical company is an important achievement of Kangtai Bio's internationalization strategy.
In the future, it will further expand overseas markets such as Southeast Asia with advanced technologies and products such as 23-valent pneumonia vaccine
.
On March 2, Tianyan Pharmaceutical (ADAG.
US) announced that it has reached a research cooperation and exclusive technology licensing agreement with Sanofi (SNY.
US), and Tianyan will conduct early research and development activities using its unique safe antibody ( SAFEbody) technology to develop precision masked safe antibodies of the new generation of monoclonal and bispecific antibodies provided by Sanofi, and Sanofi will be responsible for further research and development, product development and commercialization activities in the future
.
According to the agreement, Sanofi will pay a down payment of US$17.
5 million (about 110 million yuan) to Tianyan, and can first start the cooperative development of two antibody candidates provided by Sanofi, and has the right to nominate two additional two Candidate antibodies are developed and commercialized
.
For future products exclusively developed and commercialized by Sanofi, Tianyan will be eligible to receive development, filing and commercial milestone payments of up to US$2.
5 billion (approximately RMB 15.
8 billion), as well as tiered franchises for global net sales of products usage fee
.
Tianyan Pharmaceutical said that it is very happy to work closely with Sanofi to enable the precise masking technology of safe antibodies to enable the development of new drugs for multiple potential and challenging tumor immune targets
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.